Axovant Sciences (NASDAQ:AXON) was downgraded by equities research analysts at Cowen from an “outperform” rating to a “market perform” rating in a research report issued to clients and investors on Friday, The Fly reports.

AXON has been the topic of several other reports. BidaskClub downgraded Axovant Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. Chardan Capital reissued a “sell” rating and issued a $3.00 target price on shares of Axovant Sciences in a report on Saturday, September 23rd. Zacks Investment Research raised Axovant Sciences from a “hold” rating to a “strong-buy” rating and set a $8.00 target price on the stock in a report on Monday, October 9th. Robert W. Baird reissued a “hold” rating and issued a $6.00 target price on shares of Axovant Sciences in a report on Wednesday, November 1st. Finally, Oppenheimer reissued a “buy” rating and issued a $30.00 target price on shares of Axovant Sciences in a report on Monday, September 25th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and four have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $14.14.

Axovant Sciences (AXON) opened at $2.27 on Friday. The company has a market capitalization of $243.42 and a P/E ratio of -0.98. The company has a quick ratio of 5.94, a current ratio of 5.94 and a debt-to-equity ratio of 0.34. Axovant Sciences has a 1-year low of $2.23 and a 1-year high of $27.98.

A number of hedge funds have recently bought and sold shares of the stock. FMR LLC raised its position in Axovant Sciences by 968.5% in the 2nd quarter. FMR LLC now owns 7,235,632 shares of the biotechnology company’s stock worth $167,794,000 after purchasing an additional 6,558,462 shares during the last quarter. Capital Research Global Investors raised its position in Axovant Sciences by 21.8% in the 2nd quarter. Capital Research Global Investors now owns 3,453,800 shares of the biotechnology company’s stock worth $80,094,000 after purchasing an additional 619,226 shares during the last quarter. Janus Henderson Group PLC bought a new position in Axovant Sciences in the 2nd quarter worth approximately $47,854,000. OxFORD Asset Management LLP raised its position in Axovant Sciences by 842.1% in the 3rd quarter. OxFORD Asset Management LLP now owns 869,834 shares of the biotechnology company’s stock worth $5,838,000 after purchasing an additional 777,505 shares during the last quarter. Finally, Eagle Asset Management Inc. bought a new position in Axovant Sciences in the 3rd quarter worth approximately $4,471,000. Hedge funds and other institutional investors own 96.93% of the company’s stock.

WARNING: “Axovant Sciences (AXON) Cut to “Market Perform” at Cowen” was first published by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.watchlistnews.com/axovant-sciences-axon-cut-to-market-perform-at-cowen/1804106.html.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

The Fly

Analyst Recommendations for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with Analyst Ratings Network's FREE daily email newsletter.